Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica.
Fiche publication
Date publication
septembre 2021
Journal
The Journal of rheumatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric
Tous les auteurs :
Toussirot E, Michaud M, Wendling D, Devauchelle V
Lien Pubmed
Résumé
Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR). Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX)..
Référence
J Rheumatol. 2021 Sep 15;: